Although Akt is known as a survival kinase, inhibitors of the phosphatidylinositol 3-kinase (PI3K)–Akt pathway do not always induce substantial apoptosis. We show that silencing...
In order to pinpoint the locale of the gene for early-onset familial breast and ovarian cancer (BRCA1), polymorphisms were developed within the locus for thyroid hormone recepto...
<p>Taselisib-mediated degradation of mutant p110a occurs preferentially at the plasma membrane.</p>
<p>Activity of GDC-0077 in combination with Palbociclib and/ or Fulvestrant</p>
Activating mutations in KRAS and BRAF are found in more than 30% of all human tumours and 40% of melanoma, respectively, thus targeting this pathway could have broad therapeutic...
<p>Taselisib and GDC-0077 have increased potency in PIK3CA-mutant cancer cells</p>
<p>Taselisib depletes mutant p110a protein through ubiquitin and proteasome mechanism in a dose and time dependent manner</p>
<p>Taselisib and GDC-0077 induce mutant p110a and not WT p110a degradation</p>
<p>RTK activity plays a key role in regulating p110a degradation</p>
h-index: Number of publications with at least h citations each.